etrumadenant + itraconazole

Drug Description: Etrumadenant + itraconazole is an experimental combination of two small-molecule drugs: - Etrumadenant is an oral, small-molecule dual antagonist of adenosine A2a and A2b receptors, under evaluation mainly as an immuno-oncology agent to counteract adenosine-mediated immunosuppression in the tumor microenvironment. - Itraconazole is a triazole antifungal agent, orally bioavailable, that inhibits fungal ergosterol synthesis and is known to inhibit CYP3A4 and Hedgehog signaling. This combination does not represent a marketed product or established therapeutic regimen, but each component can affect the metabolism and efficacy of the other due to itraconazole's strong CYP3A4 inhibition. There is no evidence in the provided sources or the clinical literature to suggest the combination has been studied or developed for a specific indication, and it is not an established pharmaceutical product.

Other names

AB928 + itraconazole